A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

NCT02537483 | Unknown Phase 2

• 1 other identifier: V01-120A-201
• Study Type: interventional
• Target: 350
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary objective of this study is to compare the efficacy, safety, and tolerability of IDP-120 Gel to IDP-120 Component A, IDP-120 Component B, and IDP-120 Vehicle Gel in subjects with moderate to severe acne vulgaris.

Conditions

Acne Vulgaris

Outcome Measures

Primary Outcomes (3)

• Absolute change from Baseline to Week 12 in mean inflammatory lesion counts

  At each visit the Evaluator will count the total number of inflammatory lesions (papules, pustules, and nodules) on the subject's face. Inflammatory lesions are defined as follows: Papule - a small, solid elevation less than 5 mm in diameter. Most of the lesion is above the surface of the skin. Pustule - a small, circumscribed elevation less than 5 mm in diameter that contains yellow-white exudate. Nodule - a subcutaneous lesion greater than or equal to 5 mm in diameter.

  12 weeks

• Absolute change from Baseline to Week 12 in mean non-inflammatory lesion counts

  At each visit the Evaluator will count the total number of non-inflammatory lesions (open and closed comedones). Non-inflammatory lesions are defined as follows: Open comedones (black head) - a lesion in which the follicle opening is widely dilated with the contents protruding out onto the surface of the skin. Closed comedones (white head)- a lesion in which the follicle opening is closed, but the sebaceous gland is enlarged by the pressure of the sebum build up, which in turn causes the skin around the follicle to thin and become elevated with a white appearance.

  12 weeks

• Percent of subjects who achieve at least a two-grade reduction from baseline and are Clear or Almost Clear at Week 12 in the Evaluator's Global Severity Score.

  At each visit the severity will be determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations will be scored on a scale of 0-4 (Evaluator's Global Severity Score), with 0 being clear and 4 being severe. Please see below for complete definitions. 0\. Clear - Normal, clear skin with no evidence of acne vulgaris 1. Almost clear- Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red) 2. Mild- Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions) 3. Moderate-Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one nodulo-cystic lesion 4. Severe- Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be up to 2 nodulo-cystic lesions.

  12 weeks

Secondary Outcomes (3)

• Absolute change in inflammatory and non-inflammatory lesion counts from baseline at Weeks 2, 4, and 8.

  2, 4, and 8 weeks

• Percent of subjects who achieve at least a two-grade reduction from baseline and are Clear or Almost Clear at Week 2, 4, and 8 in the Evaluator's Global Severity Score

  2, 4, and 8 weeks

• Mean percent change in inflammatory and non-inflammatory lesion counts form baseline at Weeks 2, 4, 8, and 12.

  2, 4, 8, and 12 weeks

Study Arms (4)

IDP-120 Gel

EXPERIMENTAL

IDP-120 Gel, applied topically to the face once daily for 12 weeks.

Drug: IDP-120 Gel

IDP-120 Component A

ACTIVE COMPARATOR

IDP-120 Component A, applied topically to the face once daily for 12 weeks

Drug: IDP-120 Component A

IDP-120 Component B

ACTIVE COMPARATOR

IDP-120 Component B, applied topically to the face once daily for 12 weeks

Drug: IDP-120 Component B

IDP-120 Vehicle Gel

PLACEBO COMPARATOR

IDP-120 Vehicle Gel, applied topically to the face once daily for 12 weeks

Drug: IDP-120 Vehicle Gel

Interventions

IDP-120 Gel DRUG

Investigational Product: IDP-120 Gel

IDP-120 Gel

IDP-120 Component A DRUG

Comparator Product: IDP-120 Component A

IDP-120 Component A

IDP-120 Component B DRUG

Comparator Product: IDP-120 Component B

IDP-120 Component B

IDP-120 Vehicle Gel DRUG

Comparator Product: IDP-120 Vehicle Lotion

IDP-120 Vehicle Gel

Eligibility Criteria

• Age: 9 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female at least 9 years of age and older
• Written and verbal informed consent must be obtained.
• Subject must have a score of moderate or severe on the Evaluator's Global Severity assessment at the screening and baseline visit
• Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at screening and baseline visits
• Subjects must be willing to comply with study instructions and return to the clinic for required visits.

You may not qualify if:

• Any dermatological conditions on the face that could interfere with clinical evaluations
• Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive
• Subjects with a facial beard or mustache that could interfere with the study assessments
• Subjects who are unable to communicate or cooperate with the Investigator
• Subjects with any underlying disease that the Investigator deems uncontrolled and poses a concern for the subject's safety while participating in the study

Sponsors & Collaborators

• Valeant Pharmaceuticals: lead

MeSH Terms

Conditions

Acne Vulgaris

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Study Officials

• Anya Loncaric, MS

  Valeant Pharmaceuticals

  STUDY DIRECTOR

Central Study Contacts

Anya Loncaric, MS

CONTACT

510-259-5284; aloncaric@solta.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2015
• First Posted: September 1, 2015
• Study Start: October 1, 2015
• Primary Completion: September 1, 2016
• Study Completion: September 1, 2016
• Last Updated: September 14, 2015

Record last verified: 2015-09